RA Capital Healthcare Fund LP's Form 4 filing
Bambusa Therapeutics, Inc.BBTX · filed Nov 3, 2026
- Accession no.
- 0001231919-26-001533
- Filed
- Nov 3, 2026, 6:09 PM ET
- Trade date
- Oct 30-Nov 2, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market purchases total $46.6M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund III, L.P.CIK 0001883840 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Common Stock | PPurchaseAcquired | +189,909 | $14.23F1 | +$2,702,405.07 | 189,909 | Indirect | |
| Oct 30, 2026 | Common Stock | PPurchaseAcquired | +263,911 | $14.92F4 | +$3,937,552.12 | 453,820 | Indirect | |
| Nov 2, 2026 | Common Stock | CConversionAcquired | +3,144,858 | –F5 | – | 3,598,678 | Indirect | |
| Nov 2, 2026 | Common Stock | CConversionAcquired | +1,331,080 | –F5 | – | 1,331,080 | Indirect | |
| Nov 2, 2026 | Common Stock | PPurchaseAcquired | +2,335,109 | $16.00 | +$37,361,744 | 5,933,787 | Indirect | |
| Nov 2, 2026 | Common Stock | PPurchaseAcquired | +164,891 | $16.00 | +$2,638,256 | 1,495,971 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Common Stock | CConversionDisposed | −2,844,910 | $0.00 | $0 | 0 | Indirect | |
| Nov 2, 2026 | Common Stock | CConversionDisposed | −1,278,148 | $0.00 | $0 | 0 | Indirect | |
| Nov 2, 2026 | Common Stock | CConversionDisposed | −299,948 | $0.00 | $0 | 0 | Indirect | |
| Nov 2, 2026 | Common Stock | CConversionDisposed | −52,932 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.61 to $14.58 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $15.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
Referenced by the price of 2 transactions in Table I.
Remarks
Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.